Atorvastatin vs pravastatin
Pro Research Analysisby 
Searched over 200M research papers
LDL Cholesterol and Lipid-Lowering Efficacy: Atorvastatin vs Pravastatin
Multiple studies consistently show that atorvastatin is more effective than pravastatin at lowering low-density lipoprotein cholesterol (LDL-C) and total cholesterol in patients with hypercholesterolemia and after cardiac transplant. Atorvastatin at 10 mg or 20 mg daily reduces LDL-C by 35–46%, while pravastatin at 20–40 mg daily achieves a 23–30% reduction. More patients on atorvastatin reach target LDL-C levels compared to those on pravastatin. Atorvastatin also leads to greater reductions in triglycerides and apolipoprotein B, and is more effective at lowering malondialdehyde-modified LDL, a marker of oxidative stress, than pravastatin 126.
Cardiovascular Outcomes After Acute Coronary Syndromes
In patients who have experienced acute coronary syndromes, high-dose atorvastatin (80 mg) reduces both first and recurrent cardiovascular events more than moderate-dose pravastatin (40 mg). This results in fewer total cardiovascular events and supports the use of intensive lipid-lowering therapy with atorvastatin for secondary prevention .
Effects on Oxidative Stress and Endothelial Function
Atorvastatin demonstrates a greater reduction in markers of oxidative stress, such as lipid hydroperoxides and thiobarbituric acid reactive substances, compared to pravastatin. Both statins improve endothelial function, but the reduction in oxidative stress is more pronounced with atorvastatin, which may contribute to its superior clinical outcomes 24.
Glucose Tolerance, Adipokines, and Inflammatory Markers
Atorvastatin reduces inflammatory markers (such as high-sensitivity C-reactive protein and tumor necrosis factor-alpha) and increases adiponectin levels more than pravastatin. However, neither statin significantly affects glucose tolerance in most patients, though atorvastatin may increase HbA1c in obese individuals .
Lipoprotein(a) Levels
Both atorvastatin and pravastatin increase lipoprotein(a) [Lp(a)] levels, but atorvastatin causes a greater increase. This effect is consistent across multiple statin trials and may have implications for residual cardiovascular risk .
Effects on Lipoprotein Lipase and Mitochondrial Function
Both statins increase pre-heparin lipoprotein lipase mass, especially in patients with initially low levels, which may benefit lipid metabolism in type 2 diabetes. However, only atorvastatin has been shown to inhibit cardiac Akt/mTOR signaling and disturb mitochondrial ultrastructure in cardiac myocytes, raising potential concerns about long-term cardiac effects, particularly in susceptible individuals 78.
Cellular and Molecular Effects
Both atorvastatin and pravastatin stimulate nitric oxide and reactive oxygen species generation in endothelial cells, activate proinflammatory responses, and alter mitochondrial network architecture. They also increase nicotinamide N-methyltransferase (NNMT) protein levels, which may affect gene activity through changes in histone methylation. Pravastatin, but not atorvastatin, substantially reduces total histone H3 levels .
Safety and Tolerability
The safety and adverse event profiles of atorvastatin and pravastatin are similar, with no significant differences in clinically relevant laboratory abnormalities reported in comparative studies 16.
Conclusion
Atorvastatin is generally more potent than pravastatin in lowering LDL cholesterol, total cholesterol, triglycerides, and markers of oxidative stress, and is more effective at reducing cardiovascular events after acute coronary syndromes. However, atorvastatin may have a greater impact on Lp(a) levels and, in rare cases, may affect cardiac mitochondrial structure. Both drugs are well tolerated, but the choice between them should consider individual patient risk factors, comorbidities, and potential side effects.
Sources and full results
Most relevant research papers on this topic